These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 16231954)

  • 1. Drugs, QTc interval prolongation and final ICH E14 guideline : an important milestone with challenges ahead.
    Shah RR
    Drug Saf; 2005; 28(11):1009-28. PubMed ID: 16231954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drugs, QT interval prolongation and ICH E14: the need to get it right.
    Shah RR
    Drug Saf; 2005; 28(2):115-25. PubMed ID: 15691222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statistical issues including design and sample size calculation in thorough QT/QTc studies.
    Zhang J; Machado SG
    J Biopharm Stat; 2008; 18(3):451-67. PubMed ID: 18470755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. International Conference on Harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice.
    Food and Drug Administration, HHS
    Fed Regist; 2005 Oct; 70(202):61134-5. PubMed ID: 16237860
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical evaluation of QT/QTc prolongation and proarrhythmic potential for nonantiarrhythmic drugs: the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use E14 guideline.
    Darpo B; Nebout T; Sager PT
    J Clin Pharmacol; 2006 May; 46(5):498-507. PubMed ID: 16638733
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ICH S7B draft guideline on the non-clinical strategy for testing delayed cardiac repolarisation risk of drugs: a critical analysis.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2005 May; 4(3):509-30. PubMed ID: 15934857
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Time for a Fully Integrated Nonclinical-Clinical Risk Assessment to Streamline QT Prolongation Liability Determinations: A Pharma Industry Perspective.
    Vargas HM; Rolf MG; Wisialowski TA; Achanzar W; Bahinski A; Bass A; Benson CT; Chaudhary KW; Couvreur N; Dota C; Engwall MJ; Michael Foley C; Gallacher D; Greiter-Wilke A; Guillon JM; Guth B; Himmel HM; Hegele-Hartung C; Ito M; Jenkinson S; Chiba K; Lagrutta A; Levesque P; Martel E; Okai Y; Peri R; Pointon A; Qu Y; Teisman A; Traebert M; Yoshinaga T; Gintant GA; Leishman DJ; Valentin JP
    Clin Pharmacol Ther; 2021 Feb; 109(2):310-318. PubMed ID: 32866317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.
    Salvi V; Karnad DR; Panicker GK; Kothari S
    Br J Pharmacol; 2010 Jan; 159(1):34-48. PubMed ID: 19775279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.
    Darpo B
    Br J Pharmacol; 2010 Jan; 159(1):49-57. PubMed ID: 19922536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICH E14 Q & A (R1) document: perspectives on the updated recommendations on thorough QT studies.
    Shah RR; Morganroth J
    Br J Clin Pharmacol; 2013 Apr; 75(4):959-65. PubMed ID: 22905923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Translational Models and Tools to Reduce Clinical Trials and Improve Regulatory Decision Making for QTc and Proarrhythmia Risk (ICH E14/S7B Updates).
    Strauss DG; Wu WW; Li Z; Koerner J; Garnett C
    Clin Pharmacol Ther; 2021 Feb; 109(2):319-333. PubMed ID: 33332579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of electrocardiograms in clinical trials: a public discussion of the proposed ICH E14 regulatory guidance. April 11-12, 2005, Bethesda, MD, USA.
    Cavero I; Crumb W
    Expert Opin Drug Saf; 2005 Jul; 4(4):795-9. PubMed ID: 16011455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the in Vivo QTc assay: The value of implementing best practices to support an integrated nonclinical-clinical QTc risk assessment and TQT substitute.
    Vargas HM; Rossman EI; Wisialowski TA; Nichols J; Pugsley MK; Roche B; Gintant GA; Greiter-Wilke A; Kleiman RB; Valentin JP; Leishman DJ
    J Pharmacol Toxicol Methods; 2023; 121():107265. PubMed ID: 36997076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Utility of positive controls in assessing assay sensitivity in ICH S7B and ICH E14 guidance for evaluation of QT/QTc interval prolongation.
    Chiang AY; Mallinckrodt CH; Dmitrienko AA; Leishman DJ
    J Pharmacol Toxicol Methods; 2010; 62(2):143-7. PubMed ID: 20570744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The New S7B/E14 Question and Answer Draft Guidance for Industry: Contents and Commentary.
    Darpo B; Ferber G
    J Clin Pharmacol; 2021 Oct; 61(10):1261-1273. PubMed ID: 33896027
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ICH E14 Q&A(R2) document: commentary on the further updated recommendations on thorough QT studies.
    Shah RR; Morganroth J; Kleiman RB
    Br J Clin Pharmacol; 2015 Mar; 79(3):456-64. PubMed ID: 25060671
    [No Abstract]   [Full Text] [Related]  

  • 17. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications.
    Giorgi MA; Bolaños R; Gonzalez CD; Di Girolamo G
    Curr Drug Saf; 2010 Jan; 5(1):54-7. PubMed ID: 20210719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best practice considerations for nonclinical in vivo cardiovascular telemetry studies in non-rodent species: Delivering high quality QTc data to support ICH E14/S7B Q&As.
    Rossman EI; Wisialowski TA; Vargas HM; Valentin JP; Rolf MG; Roche BM; Riley S; Pugsley MK; Nichols J; Li D; Leishman DJ; Kleiman RB; Greiter-Wilke A; Gintant GA; Engwall MJ; Delaunois A; Authier S
    J Pharmacol Toxicol Methods; 2023; 123():107270. PubMed ID: 37164235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessing proarrhythmic potential of drugs when optimal studies are infeasible.
    Rock EP; Finkle J; Fingert HJ; Booth BP; Garnett CE; Grant S; Justice RL; Kovacs RJ; Kowey PR; Rodriguez I; Sanhai WR; Strnadova C; Targum SL; Tsong Y; Uhl K; Stockbridge N
    Am Heart J; 2009 May; 157(5):827-36, 836.e1. PubMed ID: 19376308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do Studies Evaluating QT/QTc Interval Prolongation with Dietary Supplements Meet FDA Standards: A Systematic Review.
    Nguyen TA; Kurian A; Leong J; Patel UM; Shah SA
    J Diet Suppl; 2017 Jul; 14(4):467-477. PubMed ID: 27937000
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.